Literature DB >> 28677272

Bayesian nonparametric statistics: A new toolkit for discovery in cancer research.

Peter F Thall1, Peter Mueller2, Yanxun Xu3, Michele Guindani4.   

Abstract

Many commonly used statistical methods for data analysis or clinical trial design rely on incorrect assumptions or assume an over-simplified framework that ignores important information. Such statistical practices may lead to incorrect conclusions about treatment effects or clinical trial designs that are impractical or that do not accurately reflect the investigator's goals. Bayesian nonparametric (BNP) models and methods are a very flexible new class of statistical tools that can overcome such limitations. This is because BNP models can accurately approximate any distribution or function and can accommodate a broad range of statistical problems, including density estimation, regression, survival analysis, graphical modeling, neural networks, classification, clustering, population models, forecasting and prediction, spatiotemporal models, and causal inference. This paper describes 3 illustrative applications of BNP methods, including a randomized clinical trial to compare treatments for intraoperative air leaks after pulmonary resection, estimating survival time with different multi-stage chemotherapy regimes for acute leukemia, and evaluating joint effects of targeted treatment and an intermediate biological outcome on progression-free survival time in prostate cancer.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian nonparametric statistics; clinical trial design; density estimation; dynamic treatment regime; targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28677272      PMCID: PMC5681362          DOI: 10.1002/pst.1819

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  10 in total

1.  Demystifying optimal dynamic treatment regimes.

Authors:  Erica E M Moodie; Thomas S Richardson; David A Stephens
Journal:  Biometrics       Date:  2007-06       Impact factor: 2.571

2.  Estimation and extrapolation of optimal treatment and testing strategies.

Authors:  James Robins; Liliana Orellana; Andrea Rotnitzky
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

3.  Causal effect models for realistic individualized treatment and intention to treat rules.

Authors:  Mark J van der Laan; Maya L Petersen
Journal:  Int J Biostat       Date:  2007       Impact factor: 0.968

4.  Doubly Robust Learning for Estimating Individualized Treatment with Censored Data.

Authors:  Y Q Zhao; D Zeng; E B Laber; R Song; M Yuan; M R Kosorok
Journal:  Biometrika       Date:  2015-03-01       Impact factor: 2.445

5.  Marginal Mean Models for Dynamic Regimes.

Authors:  S A Murphy; M J van der Laan; J M Robins
Journal:  J Am Stat Assoc       Date:  2001-12-01       Impact factor: 5.033

6.  Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia.

Authors:  Abdus S Wahed; Peter F Thall
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2013-01       Impact factor: 1.864

7.  Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome.

Authors:  Rebecca Graziani; Michele Guindani; Peter F Thall
Journal:  Biometrics       Date:  2014-10-15       Impact factor: 2.571

8.  Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times.

Authors:  Yanxun Xu; Peter Müller; Abdus S Wahed; Peter F Thall
Journal:  J Am Stat Assoc       Date:  2016-10-18       Impact factor: 5.033

9.  Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

Authors:  E H Estey; P F Thall; S Pierce; J Cortes; M Beran; H Kantarjian; M J Keating; M Andreeff; E Freireich
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

10.  Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.

Authors:  Paul Mathew; Peter F Thall; Donnah Jones; Cherie Perez; Corazon Bucana; Patricia Troncoso; Sun-Jin Kim; Isaiah J Fidler; Christopher Logothetis
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

  10 in total
  2 in total

1.  Hydra: A mixture modeling framework for subtyping pediatric cancer cohorts using multimodal gene expression signatures.

Authors:  Jacob Pfeil; Lauren M Sanders; Ioannis Anastopoulos; A Geoffrey Lyle; Alana S Weinstein; Yuanqing Xue; Andrew Blair; Holly C Beale; Alex Lee; Stanley G Leung; Phuong T Dinh; Avanthi Tayi Shah; Marcus R Breese; W Patrick Devine; Isabel Bjork; Sofie R Salama; E Alejandro Sweet-Cordero; David Haussler; Olena Morozova Vaske
Journal:  PLoS Comput Biol       Date:  2020-04-10       Impact factor: 4.475

Review 2.  A Causal Framework for Making Individualized Treatment Decisions in Oncology.

Authors:  Pavlos Msaouel; Juhee Lee; Jose A Karam; Peter F Thall
Journal:  Cancers (Basel)       Date:  2022-08-14       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.